BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 19295143)

  • 21. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
    Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
    Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
    Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease.
    Musacchio T; Yin J; Kremer F; Koprich JB; Brotchie JM; Volkmann J; Ip CW
    Behav Brain Res; 2022 Aug; 432():113968. PubMed ID: 35738338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.
    Chu Y; Morfini GA; Langhamer LB; He Y; Brady ST; Kordower JH
    Brain; 2012 Jul; 135(Pt 7):2058-73. PubMed ID: 22719003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
    Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC
    Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
    Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
    PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
    He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
    Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
    Chung CY; Koprich JB; Hallett PJ; Isacson O
    Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22474-9. PubMed ID: 20007772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.
    Khodr CE; Pedapati J; Han Y; Bohn MC
    Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced α-synucleinopathy.
    Crabbé M; Van der Perren A; Kounelis S; Lavreys T; Bormans G; Baekelandt V; Casteels C; Van Laere K
    Exp Neurol; 2019 Oct; 320():112964. PubMed ID: 31136763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
    Bassil F; Guerin PA; Dutheil N; Li Q; Klugmann M; Meissner WG; Bezard E; Fernagut PO
    Mov Disord; 2017 Aug; 32(8):1230-1239. PubMed ID: 28556404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct detection of alpha synuclein oligomers in vivo.
    Dimant H; Kalia SK; Kalia LV; Zhu LN; Kibuuka L; Ebrahimi-Fakhari D; McFarland NR; Fan Z; Hyman BT; McLean PJ
    Acta Neuropathol Commun; 2013 May; 1():6. PubMed ID: 24252244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.
    Gleave JA; Arathoon LR; Trinh D; Lizal KE; Giguère N; Barber JHM; Najarali Z; Khan MH; Thiele SL; Semmen MS; Koprich JB; Brotchie JM; Eubanks JH; Trudeau LE; Nash JE
    Neurobiol Dis; 2017 Oct; 106():133-146. PubMed ID: 28673739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
    Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.